ethyl 6-chloro-3-(3-hydroxypropyl)-1H-indole-2-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 6-chloro-3-(3-hydroxypropyl)-1H-indole-2-carboxylate
• 化学式: C₁₄H₁₆ClNO₃
• 分子量: 281.739
• InChiKey: HXZWWKNQRLXNGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  62.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 6-chloro-3-(3-hydroxypropyl)-1H-indole-2-carboxylate 在 偶氮二甲酸二叔丁酯 、 三苯基膦 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 30.0h， 生成 6-chloro-3-(3-(4-chloro-3-methylphenoxy)propyl)-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design

  摘要：

  Myeloid cell leukemia 1 (Mcl-1), a member of the Bcl-2 family of proteins, is overexpressed and amplified in various cancers and promotes the aberrant survival of tumor cells that otherwise would undergo apoptosis. Here we describe the discovery of potent and selective Mcl-1 inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified two chemically distinct hit series that bind to different sites on Mcl-1. Members of the two fragment classes were merged together to produce lead compounds that bind to Mcl-1 with a dissociation constant of <100 nM with selectivity for Mcl-1 over Bcl-xL and Bcl-2. Structures of merged compounds when complexed to Mcl-1 were obtained by X-ray crystallography and provide detailed information about the molecular recognition of small-molecule ligands binding Mcl-1. The compounds represent starting points for the discovery of clinically useful Mcl-1 inhibitors for the treatment of a wide variety of cancers.

  DOI：

  10.1021/jm301448p
• 作为产物：
  描述：

  ethyl 6-chloro-3-(3-ethoxy-3-oxopropyl)-1H-indole-2-carboxylate 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以83%的产率得到ethyl 6-chloro-3-(3-hydroxypropyl)-1H-indole-2-carboxylate
  参考文献：
  名称：

  CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS

  摘要：

  揭示了Mcl-1选择性抑制剂、Bcl-2选择性抑制剂以及Mcl-1/Bcl-2双重抑制剂，以及利用它们用于治疗疾病的方法。

  公开号：

  US20200299285A1

文献信息

• [EN] SUBSTITUTED INDOLE MCL-1 INHIBITORS<br/>[FR] INHIBITEURS DE MCL-1 DE TYPE INDOLE SUBSTITUÉ
  申请人：UNIV VANDERBILT

  公开号：WO2015031608A1

  公开（公告）日：2015-03-05

  The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.

  本申请提供了能够抑制抗凋亡Bcl-2家族蛋白活性的化合物，例如髓细胞白血病-1（Mcl-1）蛋白。本发明还提供了药物组合物以及使用提供的化合物治疗由Mcl-1蛋白过度表达或失调所致的疾病和情况（例如癌症）的方法。在一些实施例中，提供的化合物具有结构式I的结构。在一些实施例中，提供的化合物具有结构式II的结构。
• SUBSTITUTED INDOLE MCL-1 INHIBITORS
  申请人：VANDERBILT UNIVERSITY

  公开号：US20160214934A1

  公开（公告）日：2016-07-28

  The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.

  本申请提供了一些化合物，其中包括能够抑制抗凋亡Bcl-2家族蛋白（例如髓系细胞白血病-1（Mcl-1）蛋白）活性的化合物。本发明还提供了制药组合物以及使用所提供化合物治疗由Mcl-1蛋白过度表达或调节失常所致的疾病和病况（例如癌症）的方法。在某些实施例中，所提供的化合物具有公式I的结构。在某些实施例中，所提供的化合物具有公式II的结构。
• SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS
  申请人：VANDERBILT UNIVERSITY

  公开号：US20150336925A1

  公开（公告）日：2015-11-26

  The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

  本发明提供了一种抑制抗凋亡Bcl-2家族成员髓系细胞白血病-1（Mcl-1）蛋白活性的化合物。本发明还提供了制药组合物以及使用化合物治疗因Mcl-1蛋白过度表达或失调而表现出的疾病和症状（例如癌症）的方法。
• Pd/C Catalyzed Dehalogenation of (Hetero)aryls Using Triethyl­silane as Hydrogen Donor
  作者：Matthieu Jouffroy、Mathéo La Torre、William Maton、Ed Cleator

  DOI：10.1055/s-0042-1753402

  日期：——

  performed using hydrogen gas and a metal supported on carbon, notably palladium (Pd/C). Though efficient, the need for a milder and operationally simple dehalogenation can arise. We found that the combination of Pd/C as catalyst and triethylsilane (TES) as hydrogen donor in THF resulted in a broadly applicable, easy to set up, and scalable debromination and deiodination. Optimization of the reaction showed

  (杂)芳基脱卤是一种经典的转化，通常使用氢气和负载在碳上的金属，尤其是钯 (Pd/C)。尽管高效，但可能会出现对更温和且操作简单的脱卤的需求。我们发现 Pd/C 作为催化剂和三乙基硅烷 (TES) 作为氢供体在 THF 中的组合产生了广泛适用、易于设置和可扩展的脱溴和脱碘。反应优化表明，室温下 1 mol% 的 Pd/C 和 4 当量的 TES 足以在 4-24 小时内获得大多数具有药学意义的合成子的完全转化。新发现的条件适用于各种芳香族和杂芳族底物，以良好到极好的产率提供所需的目标，并具有出色的官能团耐受性。
• Substituted indole Mcl-1 inhibitors
  申请人：Vanderbilt University

  公开号：US10005728B2

  公开（公告）日：2018-06-26

  The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.

  本申请除其他外，提供了能够抑制抗凋亡 Bcl-2 家族蛋白（例如髓系细胞白血病-1（Mcl-1）蛋白）活性的化合物。本发明还提供了药物组合物以及使用所提供的化合物治疗以 Mcl-1 蛋白过度表达或失调为特征的疾病和病症（如癌症）的方法。在某些实施方案中，所提供的化合物具有式I的结构。